Given the independent mechanisms involved in progressive fibrosis by PNPLA3 rs738409 and SIRT5 rs12216101, these two variants might synergistically increase the risk of advanced fibrosis in MASLD. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.